39:, United States. He previously served as the Executive Medical Director of Oncologic Services and the Senior Medical Director for the Oncology Clinical Program at Intermountain Healthcare, serving 23 hospitals and >6000 patients across the State of Utah and beyond. He was also Professor of Surgery at the University of Utah and a Member of the Huntsman Cancer Institute's Cellular Response and Regulation Program. Dr Yeatman was also the Director of Gibbs Cancer Center and President of
116:. He has spent more than 10 years in the field of molecular profiling and gene expression classifier development, working in the environment of team science and multidisciplinary collaboration. Yeatman has active and completed grants funded by NCI as well as the state of Florida. Yeatman holds numerous patents that include the identification of the first human mutations in the SRC
124:
personalized medicine, and served as the president and founding chief scientific officer of M2Gen (a wholly owned subsidiary of the MCC that implemented and managed the TCC project). He participated in recruiting a nationwide network of 18 hospitals (TCC Consortium) that collected, macrodissected, curated and profiled more than 20,000 snap frozen tumor samples on a single
52:(MCC) in Florida over a 20 year span from 1992 - 2012. Yeatman served as the Associate Center Director for Clinical Investigations, the Associate Center Director for Translational Research, the Executive Vice President for Translational Research, Professor of Surgery and Cncologic Sciences, and the GI Tumor Program Leader at the Moffitt Cancer Center and the
476:
Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
475:
Director's
Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B,
140:
Yeatman has received numerous honors and awards including the James IV Association of
Surgeons Traveling Fellowship, Europe; the Center Director's Award for Outstanding Research at Moffitt Cancer Center; and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, and the Million
123:
Yeatman is a pioneer in personalized medicine, having headed the development of the world's largest human tumor bio-repository and database with comprehensive molecular profiling of approximately 20,000 tumor specimens. He was the principal architect of the Total Cancer Care (TCC) initiative in
141:
Dollar
Researcher award at the University of South Florida. Yeatman has been continuously funded through additional grants from the American Cancer Society, including a Director's Challenge Award for the global profiling of human colon cancer. He is a member of numerous societies including the
17:
561:
Hegde P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh NU, Chen T, Saeed AI, Sharov V, Lee NH, Yeatman TJ, Quackenbush J. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray.
56:. There he led a $ 100m Moffitt:Merck collaboration and co-founded a novel biotech company, M2Gen. He also served as Chief Scientific Officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by
47:
where he founded the
Guardian Research Network, a novel approach to clinical data analytics, leveraging the entire EHR for real time database queries for identifying clinical trial candidates. Yeatman held numerous positions at the
258:
389:
539:
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.
128:
platform with a commercial pipeline. Yeatman also served as chair of the Joint
Scientific Committee, and the co-chair of the Joint Operating Committee, which made him the primary liaison with
625:
Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype.
64:. He has been funded by the National Cancer Institute (NCI) since 1993 and continues to perform basic and translational colorectal cancer research in genomics and biomarker development.
518:
Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
262:
233:
604:
Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis coli.
454:
Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers.
120:(Patent Number 7803909) and methods for matching patients to clinical trials using a molecular database (Patent Numbers 8175896, 8095389, 20110288890, 20080033658).
433:
Attallah AM, Yeatman TJ, Noguchi PD, Johnson JB. Antibody-dependent cell-mediated cytotoxicity: detection by automated flow cytometry with ultramicro techniques.
112:(NCI) since 1993. He spent 20 years at the Moffitt Cancer Center as a physician scientist, with a clinical and research focus on the problems linked to
583:
Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells.
403:
357:
339:
201:
40:
28:
237:
175:
146:
259:"CASIS Names Dr. Timothy J. Yeatman Interim Chief Scientist - CASIS - Center for the Advancement of Science in Space"
31:(born June 10, 1958) is currently the Associate Center Director for Translational Research and Innovation for the
149:. He has published around 150 articles in the top peer-reviewed journals in his field, including the prestigious
652:
142:
283:
61:
53:
44:
36:
300:
410:
361:
343:
181:
109:
93:
202:"Meet Our Leadership | Gibbs Cancer Center | Spartanburg, SC | Gibbs Cancer Center"
205:
32:
340:"Moffitt promotes Timothy Yeatman to M2Gen chief science officer - Tampa Bay Business Journal"
169:
97:
89:
49:
132:
in developing and managing the more than $ 150 million project and the derivative science.
375:
8:
73:
630:
609:
588:
567:
545:
523:
502:
481:
459:
438:
326:"Timothy Yeatman Inventions, Patents and Patent Applications - Justia Patents Search"
325:
151:
113:
358:"Moffitt, Merck break ground on collaborative project - Tampa Bay Business Journal"
85:
163:
157:
77:
129:
81:
646:
634:
613:
592:
571:
549:
527:
506:
485:
463:
442:
304:
125:
117:
16:
88:
and completed his surgical internship and residency at the
57:
376:"James IV Association of Surgeons | Members"
35:Cancer Institute and Professor of Surgery at the
644:
145:and the Society of Surgical Oncology and the
92:, and then a surgical oncology fellowship at
295:
293:
108:Yeatman has been continuously funded by the
41:Gibbs Cancer Center & Research Institute
76:. He received his undergraduate degree at
290:
228:
226:
224:
222:
135:
80:, where he graduated summa cum laude and
542:Journal of the National Cancer Institute
520:Journal of the National Cancer Institute
176:Journal of the National Cancer Institute
147:American Association for Cancer Research
15:
645:
219:
103:
84:. He received his medical degree from
60:to oversee all scientific use of the
497:Yeatman TJ. A renaissance for SRC.
13:
14:
664:
501:. 2004 Jun;4(6):470-80. Review.
619:
598:
577:
555:
533:
522:. 2011 Dec 21;103(24):1859-70.
512:
491:
469:
448:
437:. 1980 Jul 18;209(4454):404-6.
427:
396:
382:
368:
350:
332:
318:
301:"Patentfish.com Search (dead)"
276:
251:
194:
1:
629:. 2005 Mar 1;65(5):1814-21.
608:. 2003 Aug 1;63(15):4368-74.
188:
143:American Surgical Association
67:
587:. 2002 May 1;62(9):2669-74.
566:. 2001 Nov 1;61(21):7792-7.
234:"Timothy Joseph Yeatman, MD"
7:
544:. 2002 Apr 3;94(7):513-21.
62:International Space Station
54:University of South Florida
45:Spartanburg, South Carolina
37:University of South Florida
10:
669:
458:. 1999 Feb;21(2):187-90.
110:National Cancer Institute
94:MD Anderson Cancer Center
480:. 2008 Aug;14(8):822-7.
404:"Dr. Timothy J. Yeatman"
96:, prior to arriving at
136:Awards and recognition
33:Tampa General Hospital
25:Timothy Joseph Yeatman
21:
499:Nature Reviews Cancer
170:Nature Reviews Cancer
98:Moffitt Cancer Center
90:University of Florida
50:Moffitt Cancer Center
19:
653:American oncologists
72:Yeatman was born in
284:"RePORT ⟩ RePORTER"
104:Career and research
20:Dr. Timothy Yeatman
392:. 17 October 2023.
74:Cheverly, Maryland
22:
173:, as well as the
114:colorectal cancer
660:
638:
623:
617:
602:
596:
581:
575:
559:
553:
537:
531:
516:
510:
495:
489:
473:
467:
452:
446:
431:
425:
424:
422:
421:
415:
409:. Archived from
408:
400:
394:
393:
386:
380:
379:
372:
366:
365:
360:. Archived from
354:
348:
347:
342:. Archived from
336:
330:
329:
322:
316:
315:
313:
312:
303:. Archived from
297:
288:
287:
280:
274:
273:
271:
270:
261:. Archived from
255:
249:
248:
246:
245:
236:. Archived from
230:
217:
216:
214:
213:
204:. Archived from
198:
86:Emory University
668:
667:
663:
662:
661:
659:
658:
657:
643:
642:
641:
627:Cancer Research
624:
620:
606:Cancer Research
603:
599:
585:Cancer Research
582:
578:
564:Cancer Research
560:
556:
538:
534:
517:
513:
496:
492:
478:Nature Medicine
474:
470:
456:Nature Genetics
453:
449:
432:
428:
419:
417:
413:
406:
402:
401:
397:
388:
387:
383:
374:
373:
369:
356:
355:
351:
338:
337:
333:
324:
323:
319:
310:
308:
299:
298:
291:
282:
281:
277:
268:
266:
257:
256:
252:
243:
241:
232:
231:
220:
211:
209:
200:
199:
195:
191:
182:Cancer Research
164:Nature Medicine
158:Nature Genetics
138:
130:Merck & Co.
106:
78:Duke University
70:
12:
11:
5:
666:
656:
655:
640:
639:
618:
597:
576:
554:
532:
511:
490:
468:
447:
426:
395:
381:
367:
364:on 2007-11-17.
349:
346:on 2010-09-26.
331:
317:
289:
275:
250:
218:
192:
190:
187:
137:
134:
105:
102:
82:Phi Beta Kappa
69:
66:
9:
6:
4:
3:
2:
665:
654:
651:
650:
648:
636:
632:
628:
622:
615:
611:
607:
601:
594:
590:
586:
580:
573:
569:
565:
558:
551:
547:
543:
536:
529:
525:
521:
515:
508:
504:
500:
494:
487:
483:
479:
472:
465:
461:
457:
451:
444:
440:
436:
430:
416:on 2013-10-17
412:
405:
399:
391:
385:
377:
371:
363:
359:
353:
345:
341:
335:
327:
321:
307:on 2011-08-27
306:
302:
296:
294:
285:
279:
265:on 2013-10-21
264:
260:
254:
240:on 2013-10-17
239:
235:
229:
227:
225:
223:
208:on 2013-10-16
207:
203:
197:
193:
186:
184:
183:
178:
177:
172:
171:
166:
165:
160:
159:
154:
153:
148:
144:
133:
131:
127:
121:
119:
115:
111:
101:
99:
95:
91:
87:
83:
79:
75:
65:
63:
59:
55:
51:
46:
42:
38:
34:
30:
26:
18:
626:
621:
605:
600:
584:
579:
563:
557:
541:
535:
519:
514:
498:
493:
477:
471:
455:
450:
434:
429:
418:. Retrieved
411:the original
398:
384:
370:
362:the original
352:
344:the original
334:
320:
309:. Retrieved
305:the original
278:
267:. Retrieved
263:the original
253:
242:. Retrieved
238:the original
210:. Retrieved
206:the original
196:
180:
174:
168:
162:
156:
150:
139:
122:
107:
71:
24:
23:
420:2013-10-16
311:2013-10-16
269:2013-10-16
244:2024-06-29
212:2013-10-16
189:References
126:Affymetrix
68:Background
647:Category
635:15753379
614:12907606
593:11980666
572:11691794
550:11929952
528:22157961
507:15170449
486:18641660
390:"Stocks"
118:oncogene
29:F.A.C.S.
464:9988270
443:7384812
435:Science
152:Science
27:, M.D.
633:
612:
591:
570:
548:
526:
505:
484:
462:
441:
179:, and
414:(PDF)
407:(PDF)
631:PMID
610:PMID
589:PMID
568:PMID
546:PMID
524:PMID
503:PMID
482:PMID
460:PMID
439:PMID
58:NASA
185:,.
43:in
649::
292:^
221:^
167:,
161:,
155:,
100:.
637:.
616:.
595:.
574:.
552:.
530:.
509:.
488:.
466:.
445:.
423:.
378:.
328:.
314:.
286:.
272:.
247:.
215:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
